Skip to main content
. 2020 Dec 15;324(23):2383–2395. doi: 10.1001/jama.2020.23027

Table 4. Adverse Events Through 2 Years.

No. (%)
Aflibercept
(n = 100)
Vitrectomy and
panretinal
photocoagulation
(n = 105)
Ocular adverse events occurring in study eyes: participants with ≥1 event
Cataract extraction or visually significant cataract on clinical examination (eyes with natural lens only) (n = 75)
37 (49)
(n = 81)
36 (44)
Visually significant cataract (n = 75)
34 (45)
(n = 81)
35 (43)
Cataract extraction (n = 75)a
23 (31)
(n = 81)
22 (27)
Adverse intraocular pressure event 23 (23) 25 (24)
Increase in intraocular pressure ≥10 mm Hg from baseline 16 (16) 17 (16)
Intraocular pressure ≥30 mm Hg at any visit 8 (8) 10 (10)
Initiation of medication not in use at baseline to lower intraocular pressure 14 (14) 16 (15)
Glaucoma procedure 0 2 (2)
Retinal detachment 23 (23) 15 (14)
Traction retinal detachment 22 (22) 14 (13)
Rhegmatogenous retinal detachment 4 (4) 5 (5)
Ocular inflammation 6 (6) 4 (4)
Neovascularization of the iris 2 (2) 5 (5)
Retinal tear (without detachment) 3 (3) 2 (2)
Endophthalmitis 1 (1) 2 (2)
Neovascular glaucoma 1 (1) 2 (2)
Systemic adverse events: participants with ≥1 event
Serious adverse event 42 (42) 43 (41)
Hospitalization 39 (39) 41 (39)
Death 6 (6) 3 (3)
Vascular events defined by Antiplatelet Trialists’ Collaboration criteria
Any event 8 (8) 7 (7)
Death due to vascular or unknown cause 5 (5) 3 (3)
Nonfatal stroke 2 (2) 2 (2)
Nonfatal myocardial infarction 1 (1) 2 (2)
a

Among the 75 eyes with natural lens (ie, phakic eyes) in the initial aflibercept group at baseline, 27 underwent vitrectomy during follow-up. Of the 23 eyes that underwent cataract extraction, 9 had cataract extraction and no vitrectomy during follow-up, 3 had cataract extraction before undergoing vitrectomy (ie, these eyes were phakic at baseline but pseudophakic at time of first vitrectomy), and 11 had cataract extraction after their first vitrectomy.